# OAsIs (NCT02558816)

> A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients

No report yet. It can be ordered.

- Drugs tested: ibrutinib plus obinutuzumab plus venetoclax
- Indication: relapsed/refractory mantle cell lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02558816
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Nantes University Hospital
- Conditions: Mantle Cell Lymphoma
- Interventions: Ibrutinib + GA101 +GDC-0199
- Enrollment: 48
- Primary outcome: Step A : occurrence of unacceptable toxicity of the combination of GA101 and Ibrutinib during the first cycle of treatment
- Primary outcome: Step B : occurrence of unacceptable toxicity (definition p3) of the combination of GA101 and Ibrutinib plus GDC-0199 during the cycle 2 in terms of Dose-Limiting Toxicities (DLTs)
- Primary outcome: Step C : occurrence of unacceptable toxicity of the combination of GA101 and Ibrutinib and GDC-0199 at the end of the cycle 2

## Indexed commentary on OAsIs so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=oasis-nct02558816